Sotera Health (SHC) Puts Up a Steady Q1 2026 Backdrop as Governance Moves Enter the Room

What happened in the quarter

The medical-device sterilization and lab testing provider reported Q1 2026 net revenues up 10.0% year over year (6.5% on a constant-currency basis) versus Q1 2025. Net income totaled $27 million, or $0.09 per diluted share, reversing a $13 million net loss in the prior-year period. Adjusted EBITDA rose 10.5% (6.9% CC), and Adjusted EPS came in at $0.18—up 29% on a diluted-share basis. All of this comes alongside the company’s decision to keep its 2026 outlook intact and to flag a separate release about a planned CEO transition.

Key figures at a glance

• Net revenues: +10.0% YoY; +6.5% CC
• Net income: $27 million; $0.09 per diluted share
• Adjusted EBITDA: +10.5%; +6.9% CC
• Adjusted EPS: $0.18; +29% per diluted share
• 2026 revenue forecast reaffirmed: 5.0%–6.5% net revenues growth (CC)
• 2026 EBITDA growth: 5.5%–7.0% (CC)

Strategic context: where the growth is coming from

The release calls out Sterigenics and Nordion as engines of the quarter’s performance, with Sterigenics delivering a notable 6.1% CC revenue growth on a combined basis. The company also highlights Nelson Labs as part of its growth story, signaling ongoing momentum across its end-to-end sterilization, lab testing, and advisory services platform. The numbers align with a story of durable demand in healthcare sterilization outsourcing and related testing—areas that tend to exhibit steadier demand versus more cyclical medical device cycles.

Leadership and governance: a quiet pivot

Management flagged a separate release today about CEO transition, a move investors will parse for implications on strategy and execution cadence. On the governance front, Rich Kyle joined the Board in February, and Ken Krause was added in March. The tone in the press materials is one of prudence and continuity, but a board refresh often foreshadows a sharper strategic cadence—especially in a sector where regulatory, pricing, and supply dynamics can shift quickly.

What this could portend for SHC and its peers

This quarter reinforces a narrative of steady, if not spectacular, growth in a segment that benefits from outsourcing in sterilization and related laboratory services. The margin expansion implied by the Adjusted EBITDA uptick hints at efficiency gains or favorable mix—likely driven by higher-margin Sterigenics activity and improving operations in Nordion and related units. For peers, the takeaway is twofold: first, the ability to sustain top-line growth through price and volume/mix, even in a CC-adjusted world; second, the importance of governance and leadership clarity to translate operational performance into a credible long-run plan.

Analysts watching EPS trajectories and the gap between reported EPS and EPS consensus (where disclosed) will want to see whether Shaw-like or Sterigenics-like growth persists as macro headwinds and healthcare demand remain in flux. The absence of an explicit earnings surprise metric in the release leaves room for interpretation—read as: investors may be sizing the risk-reward around the CEO transition and the durability of the current growth drivers. In any case, the reaffirmed revenue forecast for 2026 suggests management confidence that the first quarter isn’t a one-off anomaly, but a signal of ongoing momentum.

Bottom line

SHC delivered a constructive Q1 2026, with meaningful improvements in EPS and Adjusted EPS, a solid revenue beat on a CC basis, and a reaffirmed 2026 revenue forecast and EBITDA trajectory. The governance refresh adds a layer of intrigue: can the leadership transition maintain, or accelerate, the momentum? If Sterigenics and Nordion continue to drive growth, and the board’s fresh perspectives translate into sharper capital allocation, Sotera Health could see its earnings narrative solidify—potentially lifting the stock multiple relative to peers. For sector peers, it’s a reminder that the battlelines in sterilization outsourcing and healthcare testing aren’t just about volume; they’re about disciplined governance, durable pricing power, and the art of turning CC headwinds into real growth in EPS and cash generation.